A cyclic GB virus C derived peptide with anti-HIV-1 activity targets the fusion peptide of HIV-1
- 1 October 2014
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 86, 589-604
Abstract
No abstract availableKeywords
Funding Information
- Ministerio de Economía y Competitividad, Spain (CTQ2012-37589-C02-01/02)
This publication has 46 references indexed in Scilit:
- Updating the Use of Synthetic Peptides as Inhibitors of HIV-1 EntryCurrent Medicinal Chemistry, 2014
- Synthesized Peptide Inhibitors of HIV-1 gp41-dependent Membrane FusionCurrent Pharmaceutical Design, 2013
- Can HIV-1 viral interference be used therapeutically?The Lancet Infectious Diseases, 2013
- GB virus C: the good boy virus?Trends in Microbiology, 2012
- Inhibition of HIV-1 by Fusion InhibitorsCurrent Pharmaceutical Design, 2010
- Development of Peptide and Small‐Molecule HIV‐1 Fusion Inhibitors that Target gp41ChemMedChem, 2010
- Expression of GB virus C NS5A protein from genotypes 1, 2, 3 and 5 and a 30 aa NS5A fragment inhibit human immunodeficiency virus type 1 replication in a CD4+ T-lymphocyte cell lineJournal of General Virology, 2007
- Discovery and Optimization of a Natural HIV-1 Entry Inhibitor Targeting the gp41 Fusion PeptideCell, 2007
- HIV entry inhibition by the envelope 2 glycoprotein of GB virus CAIDS, 2007
- Enfuvirtide approved for defusing HIVThe Lancet Infectious Diseases, 2003